Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer's disease progression and heterogeneity
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a heterogeneous disorder with abnormalities in multiple biological domains. In an advanced machine learning analysis of postmortem brain and in vivo blood multi-omics molecular data ( N = 1863), we integrated epigenomic, transcriptomic, proteomic, and metabolomic profiles into a multilevel biological AD taxonomy. We obtained a personalized multilevel molecular index of AD dementia progression that predicts severity of neuropathologies, and identified three robust molecular-based subtypes that explain much of the pathologic and clinical heterogeneity of AD. These subtypes present distinct patterns of alteration in DNA methylation, RNA, proteins, and metabolites, identifiable in the brain and subsequently in blood. In addition, the genetic variations that predispose to the various AD subtypes in brain predict distinct spatial patterns of alteration in cell types, suggesting a unique influence of each putative AD variant on neuropathological mechanisms. These observations support that an individually tailored multi-omics molecular taxonomy of AD may represent distinct targets for preventive or treatment interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4. Three distinctive AD subtypes identified with multi-omics molecular data from the brain (ROSMAP). (A) BIC values obtained for each considered number of putative subtypes. In statistics, the model with lowest BIC is preferred (here, three subtypes). For analyzing the stability of this selection, the subtyping was repeated 500 times via bootstrapping with replacement (presented BIC values correspond to the bootstrap average). Note that, across all bootstrap repetitions, the method always selected three as the optimum number of subtypes. (B) Cross-validation analysis for identification of the most compelling classification structure in terms of predictability of pathological advance (as quantified by the multi-omics mDPS). Note that the deconstruction of the whole population into smaller/stable subtypes brought a significant improvement in internal data homogeneity and multi-omics mDPS predictability. (C) Number of samples per subtype and corresponding significance obtained with randomization testing (all P < 0.001, few-corrected). (D and E) Subtype-specific clinical diagnoses and sex proportions, respectively. (F) Inter-subtype differences in cognitive domains and their rates of change over time [all P < 0.05, FWE-corrected, based on analysis of variance (ANOVA) tests with permutations]. Only significant differences are shown, with values corresponding to explained variance and signs reflecting direction (for slopes, a positive value would indicate stronger cognitive decline for the first specified subtype, while a negative value would indicate the contrary). (G and H) Total inter-subgroup molecular and neuropathological differences. For each omics data type and comparison with the control population, each matrix element corresponds to the percent of significantly different features (all q < 0.05, FDR-corrected, based on ANOVA tests with subtype as grouping variable; see the “Statistical analyses” section). For each AD subtype-subtype matrix element, the reported value represents the percent of data features that are abnormal for one subtype but not for the other (mismatch level).](https://figures.cochat.ai/paper-figures/336eda091ef146a4b40b9cb9e0f148a7/unified-epigenomic-transcriptomic-proteomic-and-metabolomic-taxonomy-of-figure-4.jpg)



![Fig. 8. Distinctively expressed genes in blood monocyte cells across putative AD subtypes (ROSMAP). (A) Top 50 differentially expressed genes (all q < 0.05, FDR-corrected; for the complete list, see table S5). Results are based in ANOVA tests with subtype as grouping variable, adjusting by age, sex, and educational level. The radio represents the explained variance (as a percentage, covering the scale [0, 14%]). (B) Subtype-subtype mismatch matrix (element i,j represents the percent of uncommon altered monocyte genes among subtypes i and j).](https://figures.cochat.ai/paper-figures/0e73d1ded37045f1a4b2cf04a57d86d0/unified-epigenomic-transcriptomic-proteomic-and-metabolomic-taxonomy-of-figure-8.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proteomic clustering has identified subgroups particularly responsive to drugs that modulate synaptic function and restore BBB integrity342,345,347,350,352,399,400.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [400]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These analyses have identified subtypes characterized by immune activation, mitochondrial dysfunction, lipid dysregulation, and BBB disruption342,352,399,400.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [400]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent work applying ML to real-world EHRs shows that inexpensive, routinely collected data can flag patients at elevated risk for future Alzheimer’s disease.”
From Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias (2026) · cites this paper as [123]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent studies have used gradient boosting trees and random-forest models to predict ADRD up to 5 years in advance (AUC > 0.85) or to predict AD 7 years in advance (AUC: 0.72), the latter using only diagnosis codes, prescriptions, and common laboratory results.123,124”
From Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias (2026) · cites this paper as [123]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Estimating the Dimension of a Model
Schwarz, G. (1978) · The Annals of Statistics · doi:10.1214/aos/1176344136 · Cited by 47,033
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Complex network measures of brain connectivity: Uses and interpretations
Rubinov, M., & Sporns, O. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.003 · Cited by 11,522
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814
Highly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Self-citationLarge-scale gene function analysis with the PANTHER classification system
Mi, H., Muruganujan, A., Casagrande, J. T., & Thomas, P. D. (2013) · Nature Protocols · doi:10.1038/nprot.2013.092 · Cited by 2,466
Similarity network fusion for aggregating data types on a genomic scale
Wang, B., Mezlini, A. M., Demir, F., Fiume, M., Tu, Z., Brudno, M., Haibe-Kains, B., & Goldenberg, A. (2014) · Nature Methods · doi:10.1038/nmeth.2810 · Cited by 2,036
Cited by
Cellular communities reveal trajectories of brain ageing and Alzheimer’s disease
Green, G. S., Fujita, M., Yang, H.-S., Taga, M., Cain, A., McCabe, C., Comandante-Lou, N., White, C. C., Schmidtner, A. K., Zeng, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07871-6 · Cited by 204
Self-citationRen, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
A review of neuroimaging-based data-driven approach for Alzheimer’s disease heterogeneity analysis
Liu, L., Sun, S., Kang, W., Wu, S., & Lin, L. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0033 · Cited by 16
Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias
Breithaupt, A. G., Tang, A., Paolillo, E. W., Bibars, M., Johnson, E. C. B., Saloner, R., Possin, K. L., Windon, C. C., Hill-Jarrett, T. G., Giorgio, J., et al. (2026) · Seminars in Neurology · doi:10.1055/a-2744-9871 · Cited by 6
Wei, H., Wu, C., Yuan, Y., & Lai, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1249682 · Cited by 3
“Although substantial progress has been made over the past decades, a review of available publications suggests that there is need to further dissect the heterogeneity and classification of disease subtypes of AD (Iturria-Medina et al., 2022).”
Background
Metadata
- Authors
- Iturria-Medina, Y., Adewale, Q., Khan, A. F., Ducharme, S., Rosa-Neto, P., O’Donnell, K., Petyuk, V. A., Gauthier, S., De Jager, P. L., Breitner, J., & Bennett, D. A.
- Affiliations
- Neurology and Neurosurgery Department, Montreal Neurological Institute, Montreal, Canada.
- Montreal Neurological Institute and Hospital (CA)
- McGill University Research Centre for Studies in Aging, Douglas Research Centre, Montreal, Canada.
- Yale University (US)
- Pacific Northwest National Laboratory (US)
- Douglas Mental Health University Institute (CA)
- Center for Translational and Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Rush University Medical Center (US)
- Corresponding author
- Adewale, Quadri
- Khan, Ahmed F.
- ORCID
- Venue
- Science Advances
- Published
- 2022-11-16
- Volume
- 8
- Issue
- 46
- Pages
- eabo6764-eabo6764
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC9674284
- OpenAlex
- W4309467340
- Cited by
- 100
- References
- 64
- Citations by year
- 2026: 29 · 2025: 40 · 2024: 19 · 2023: 12
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH1220012, AG024904)
- Foundation for the National Institutes of Health (W81XWH-12-2-0012, U01AG024904, DAOU16AMPA, AG024904)
- Alzheimer's Association (U01 AG024904, W81XWH-12-2-0012)
- Bristol-Myers Squibb (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Eli Lilly and Company (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Pfizer (AG024904, W81XWH-12-2-0012, U01 AG024904)
- Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904)
- University of Southern California (W81XWH-12-2-0012, U01 AG024904)
- Meso Scale Diagnostics (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904)
- Novartis Pharmaceuticals Corporation (W81XWH-12-2-0012, U01 AG024904, AG024904)
- McGill University
- Rush University
- Fondation Brain Canada
- Northern California Institute for Research and Education (U01 AG024904, W81XWH-12-2-0012)
- Ionis Pharmaceuticals
- Eisai (W81XWH-12-2-0012, U01 AG024904, AG024904)
- Novo Nordisk
- Canada First Research Excellence Fund
- Servier (AG024904, W81XWH-12-2-0012, U01 AG024904)
- H. Lundbeck A/S (U01 AG024904, AG024904, W81XWH-12-2-0012)
- IXICO (AG024904, W81XWH-12-2-0012, U01 AG024904)
- National Institutes of Health (3u01ag024904-10s2, W81XWH, W81XWH-12-2-0012, U01-AG024904, AG024904, UL1TR001863)
- Genentech (W81XWH-12-2-0012, AG024904, U01 AG024904)
- University of California, San Diego
- Health Canada
- Canadian Institutes of Health Research (U01 AG024904, W81XWH-12-2-0012)
- National Institute on Aging (U01-AG-024904, R01AG017917, RF1AG059093, RF1AG057452, RF1AG058942, RF1AG051550, R01AG015819, P30AG010161, U01AG061359, U01AG061356, R01AG046171, RF1AG036042, P30AG072975)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, disease heterogeneity, disease progression, multi-omics integration, epigenomics, DNA methylation, transcriptomics, proteomics, metabolomics, blood biomarkers, postmortem brain, molecular subtypes, genetic variants
- MeSH terms
- Alzheimer Disease, Humans, Disease Progression, Proteomics, Epigenomics, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.